Reprieve Cardiovascular introduces guided diuretic therapy at major heart failure congresses

Reprieve-guided diuretic therapy will be the subject of the two presentations at ICI 2018, the International Congress of Cardiovascular Systems , to be held 2-4 December 2018 in Tel Aviv, Israel. The company technology will be presented in the Innovation Pavilion:

• Dr. Howard Levin, Reprieve Cardiovascular’s Chief Medical Officer, presented “Optimized Volume Removal for Patients on Diuretic Resistance” as part of the “Developing Technologies in Heart Failure Diagnosis and Management” conference block .
• Representing the Congress Technology Parade , Jim Dillon, President and CEO of Reprieve Cardiovascular, will present the “Reprieve-guided Controllable Diuresis on Acute Heart Failure Patients”, the company’s proposed and tested therapeutic approach.

In addition, Professor Piotr Ponikowski, professor of cardiology at Wroclaw Medical University, 4th Military Hospital in Wroclaw, Poland, will discuss the current TARGET STUDY – The Polish Experience Using Reprieve-led Diuretic Therapy at the International Congress “Device Therapies in Heart Failure “ (D-HF), which takes place from 14 to 15 December 2018 in Frankfurt. The first feasibility results This study was presented in May at the “Heart Failure 2018”. The aim of the TARGET study is to demonstrate the use of the Guided Cardiovascular Diuretic Reprieve Therapy to optimize fluid management in ADHF patients and relieve concomitant symptoms.

“We will continue to monitor the results of Professor Ponikowski’s study and look forward to his current information at the upcoming Devices in Heart Failure Congress in December,” said Jim Dillon, President and CEO of Reprieve Cardiovascular. “Our guided diuretic therapy has the potential to establish a whole new standard in the treatment of patients with heart failure by providing physicians with maximum fluid removal while protecting patients from adverse side effects due to excessive fluid loss. We look forward to continuing discussions with leading suppliers in this important area on D-HF and ICI in December. “

Reprieve Cardiovascular uses the RenalGuard platform distributed by RenalGuard Solutions ™, Inc. For more information on Reprieve Cardiovascular and its guided diuretic therapy, we recommend that ICI and D-HF participants visit the exhibition area at each conference.

Reprieve Cardiovascular’s management team will also be present at the 37th Annual JPMorgan Healthcare Conference in San Francisco, California from January 7 to January 10, 2019 .

About the guided diuretic therapy of Reprieve Cardiovascular

Reprieve Cardiovascular’s guided diuretic therapy is used to manage fluid during diuretic therapy in patients with Acute Decompensated Heart Failure (ADHF), which also alleviates a range of symptoms associated with the condition. The therapy has the potential to provide accurate and predictable fluid balance management for patients, to guard against dangerous fluid imbalance, to ensure better control of diuretic therapy and thus to improve diuretic efficacy among patients. Potential benefits include faster discharge while protecting key organ functions

About Reprieve Cardiovascular

Reprieve Cardiovascular is a pioneering medical device company specializing in innovative fluid management technologies for heart failure. The company’s reprieve technology is currently being tested to treat innovative fluid management. Empowering clinics to accurately control patient fluid volume not only improves cardiac care, but also helps relieve patients with acute congestive heart failure (ADHF). Reprieve Cardiovascular, Inc. and RenalGuard Solutions, Inc. are affiliates of CardioRenal Systems, Inc. For more information, visit www.reprievecardio.com or follow Reprieve Cardiovascular on Twitter at @ReprieveCardio.

The source language in which the original text is published is the official and authorized version. Translations will be included for a better understanding. Only the language version published in the original is legal. Compare translations with the original language version of the publication.